866-997-4948(US-Canada Toll Free)

Bladder Cancer - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jun 2015

Category :

Cancer

No. of Pages : 464 Pages

Bladder Cancer - Pipeline Review, H1 2015

Summary

Global Markets Directs, Bladder Cancer - Pipeline Review, H1 2015, provides an overview of the Bladder Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Bladder Cancer Overview 13
Therapeutics Development 14
Pipeline Products for Bladder Cancer - Overview 14
Pipeline Products for Bladder Cancer - Comparative Analysis 15
Bladder Cancer - Therapeutics under Development by Companies 16
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 24
Bladder Cancer - Pipeline Products Glance 25
Late Stage Products 25
Clinical Stage Products 26
Early Stage Products 27
Bladder Cancer - Products under Development by Companies 28
Bladder Cancer - Products under Investigation by Universities/Institutes 36
Bladder Cancer - Companies Involved in Therapeutics Development 37
Advaxis, Inc. 37
Alligator Bioscience AB 38
Alnylam Pharmaceuticals, Inc. 39
Altor BioScience Corporation 40
Amgen Inc. 41
AndroScience Corporation 42
APIM Therapeutics AS 43
Arno Therapeutics, Inc. 44
Ascenta Therapeutics, Inc. 45
Astellas Pharma Inc. 46
AstraZeneca Plc 47
AuraSense Therapeutics, LLC 48
AVEO Pharmaceuticals, Inc. 49
AvidBiotics Corp. 50
Bavarian Nordic A/S 51
Bayer AG 52
BioCancell Ltd 53
Bioncotech Therapeutics S.L. 54
Biotest AG 55
cCAM Biotherapeutics Ltd. 56
Celgene Corporation 57
Cold Genesys, Inc. 58
Daiichi Sankyo Company, Limited 59
Dompe Farmaceutici S.p.A. 60
DormaTarg, Inc. 61
Eisai Co., Ltd. 62
Eli Lilly and Company 63
EntreChem, S.L. 64
Esperance Pharmaceuticals, Inc. 65
Evotec AG 66
F. Hoffmann-La Roche Ltd. 67
Gene Signal International SA 68
Genmab A/S 69
GlaxoSmithKline Plc 70
Heat Biologics, Inc. 71
Hutchison MediPharma Limited 72
Idera Pharmaceuticals, Inc. 73
Immunomedics, Inc. 74
Immupharma Plc 75
ImmuRx, Inc. 76
Incyte Corporation 77
Lipella Pharmaceuticals, Inc. 78
MacroGenics, Inc. 79
Marina Biotech, Inc. 80
MedImmune, LLC 81
Merck & Co., Inc. 82
Millennium Pharmaceuticals, Inc. 83
Mirati Therapeutics Inc. 84
NuCana BioMed Limited 85
Omeros Corporation 86
Oncogenex Pharmaceuticals, Inc. 87
Oncolytics Biotech Inc. 88
Oncopeptides AB 89
Ono Pharmaceutical Co., Ltd. 90
Optimum Therapeutics, LLC 91
Panacela Labs, Inc. 92
Pfizer Inc. 93
Pharma Mar, S.A. 94
Polaris Pharmaceuticals, Inc. 95
PsiOxus Therapeutics Limited 96
Qu Biologics Inc. 97
Quest PharmaTech Inc. 98
Samyang Holdings Corporation 99
Sanofi 100
SentoClone International AB 101
Serometrix, LLC 102
Shionogi & Co., Ltd. 103
Spectrum Pharmaceuticals, Inc. 104
Stemline Therapeutics, Inc. 105
Synta Pharmaceuticals Corp. 106
TARIS BioMedical, Inc. 107
Telesta Therapeutics Inc. 108
Telormedix SA 109
Theravectys S.A. 110
TheRyte Limited 111
Tolero Pharmaceuticals, Inc. 112
Transgene SA 113
Vakzine Projekt Management GmbH 114
Viralytics Ltd. 115
Viventia Biotechnologies Inc. 116
Bladder Cancer - Therapeutics Assessment 117
Assessment by Monotherapy Products 117
Assessment by Combination Products 118
Assessment by Target 119
Assessment by Mechanism of Action 124
Assessment by Route of Administration 128
Assessment by Molecule Type 130
Drug Profiles 132
ACP-196 - Drug Profile 132
ADC-1013 - Drug Profile 134
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile 136
aganirsen - Drug Profile 137
ALT-801 - Drug Profile 139
ALT-803 - Drug Profile 141
Antibody to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 143
Antisense Oligonucleotides for Bladder Cancer - Drug Profile 144
apatorsen - Drug Profile 145
apaziquone - Drug Profile 147
APL-1202 - Drug Profile 149
APTA-012 - Drug Profile 150
AR-42 - Drug Profile 151
ASC-JM.Z1 - Drug Profile 153
ASG-15ME - Drug Profile 154
AST-008 - Drug Profile 155
AT-406 - Drug Profile 156
atezolizumab - Drug Profile 159
ATX-101 - Drug Profile 162
AV-203 - Drug Profile 163
AZD-4547 - Drug Profile 164
AZD-5312 - Drug Profile 166
B-701 - Drug Profile 167
BAY-1163877 - Drug Profile 168
BC-819 - Drug Profile 169
Biologic for Superficial Bladder Cancer - Drug Profile 172
BO-110 - Drug Profile 173
BV-2711 - Drug Profile 174
CG-0070 - Drug Profile 175
CM-24 - Drug Profile 177
CV-301 - Drug Profile 178
CVA-21 - Drug Profile 180
DAB-389EGF - Drug Profile 184
Dendritic Cell Therapy to Target HER-2 for Oncology - Drug Profile 185
Drug for Bladder Cancer - Drug Profile 186
Drug for NMIBC - Drug Profile 187
Drugs to Inhibit FGFR3 for Bladder Cancer - Drug Profile 188
Drugs to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 189
dsP21-322-2'F - Drug Profile 190
DT-310 - Drug Profile 191
DT-320 - Drug Profile 192
DT-330 - Drug Profile 193
durvalumab + tremelimumab - Drug Profile 194
EC-7072 - Drug Profile 196
enadenotucirev - Drug Profile 197
enoblituzumab - Drug Profile 199
EP-400 - Drug Profile 200
epacadostat - Drug Profile 201
eribulin mesylate - Drug Profile 203
GSK-2849330 - Drug Profile 207
HMPL-453 - Drug Profile 208
HuMax-TF-ADC - Drug Profile 209
ICT-2700 - Drug Profile 210
imiquimod - Drug Profile 211
IMO-2055 - Drug Profile 212
indatuximab ravtansine - Drug Profile 214
IPP-204106 - Drug Profile 216
Lm-LLO-ISG15 - Drug Profile 218
lurbinectedin - Drug Profile 220
MDNA-55 - Drug Profile 223
MDR-09521 - Drug Profile 224
Melflufen - Drug Profile 225
mitomycin - Drug Profile 227
MMD-37K - Drug Profile 229
mocetinostat - Drug Profile 230
Monoclonal Antibodies to Inhibit VISTA for Bladder Cancer - Drug Profile 233
Monoclonal Antibody for Bladder Cancer, Lymphoma and Myeloma - Drug Profile 234
Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer - Drug Profile 235
MVAME-03 - Drug Profile 236
MVXONCO-1 - Drug Profile 237
nivolumab - Drug Profile 238
NUC-1031 - Drug Profile 244
OGX-225 - Drug Profile 246
oportuzumab monatox - Drug Profile 247
paclitaxel - Drug Profile 249
paclitaxel albumin bound - Drug Profile 251
panitumumab - Drug Profile 255
patritumab - Drug Profile 258
pegargiminase - Drug Profile 260
pelareorep - Drug Profile 263
pembrolizumab - Drug Profile 268
QBECP-SSI - Drug Profile 275
rAd-IFN - Drug Profile 276
ramucirumab - Drug Profile 278
recMAGE-A3 + AS15 - Drug Profile 284
Recombinant BCG - Pertussis Vaccine - Drug Profile 286
Recombinant Protein for Oncology and Infectious Disease - Drug Profile 287
RNAi Oligonucleotide to Inhibit TYRO-3 for Bladder Carcinoma - Drug Profile 288
RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer - Drug Profile 289
S-588410 - Drug Profile 291
sacituzumab govitecan - Drug Profile 292
sapanisertib - Drug Profile 293
SAR-408701 - Drug Profile 295
Sentoclone - Drug Profile 296
sirolimus albumin-bound - Drug Profile 297
SL-052 - Drug Profile 299
SL-601 - Drug Profile 301
Small molecule for Bladder Cancer - Drug Profile 302
Small Molecule to Antagonize GPR87 for Cancer - Drug Profile 303
Small Molecule to Inhibit TDO-2 for Cancer - Drug Profile 304
Small Molecule to Inhibit TYRO3 for Bladder Carcinoma - Drug Profile 306
Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer - Drug Profile 307
Small Molecules to Antagonize CXCR1/2 for Bladder and Prostate Cancer - Drug Profile 308
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 309
STA-128666 - Drug Profile 310
suramin hexasodium - Drug Profile 312
SX-MTR1 - Drug Profile 314
TD-210 - Drug Profile 315
TF-011 Monomethyl Auristatin E - Drug Profile 316
TG-6002 - Drug Profile 318
THR-53 - Drug Profile 319
TMX-202 - Drug Profile 320
TP-3654 - Drug Profile 321
Urocidin - Drug Profile 322
Vaccine for Urogenital Cancers - Drug Profile 324
Vaccine to Target NY-ESO-1 for Oncology - Drug Profile 325
vemurafenib - Drug Profile 326
vesigenurtucel-L - Drug Profile 330
VPM-1002 - Drug Profile 331
Bladder Cancer - Recent Pipeline Updates 333
Bladder Cancer - Dormant Projects 440
Bladder Cancer - Discontinued Products 446
Bladder Cancer - Product Development Milestones 447
Featured News & Press Releases 447
Appendix 455
Methodology 455
Coverage 455
Secondary Research 455
Primary Research 455
Expert Panel Validation 455
Contact Us 455
Disclaimer 456

List of Tables
Number of Products under Development for Bladder Cancer, H1 2015 22
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2015 23
Number of Products under Development by Companies, H1 2015 25
Number of Products under Development by Companies, H1 2015 (Contd..1) 26
Number of Products under Development by Companies, H1 2015 (Contd..2) 27
Number of Products under Development by Companies, H1 2015 (Contd..3) 28
Number of Products under Development by Companies, H1 2015 (Contd..4) 29
Number of Products under Development by Companies, H1 2015 (Contd..5) 30
Number of Products under Development by Companies, H1 2015 (Contd..6) 31
Number of Products under Investigation by Universities/Institutes, H1 2015 32
Comparative Analysis by Late Stage Development, H1 2015 33
Comparative Analysis by Clinical Stage Development, H1 2015 34
Comparative Analysis by Early Stage Development, H1 2015 35
Products under Development by Companies, H1 2015 36
Products under Development by Companies, H1 2015 (Contd..1) 37
Products under Development by Companies, H1 2015 (Contd..2) 38
Products under Development by Companies, H1 2015 (Contd..3) 39
Products under Development by Companies, H1 2015 (Contd..4) 40
Products under Development by Companies, H1 2015 (Contd..5) 41
Products under Development by Companies, H1 2015 (Contd..6) 42
Products under Development by Companies, H1 2015 (Contd..7) 43
Products under Investigation by Universities/Institutes, H1 2015 44
Bladder Cancer - Pipeline by Advaxis, Inc., H1 2015 45
Bladder Cancer - Pipeline by Alligator Bioscience AB, H1 2015 46
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 47
Bladder Cancer - Pipeline by Altor BioScience Corporation, H1 2015 48
Bladder Cancer - Pipeline by Amgen Inc., H1 2015 49
Bladder Cancer - Pipeline by AndroScience Corporation, H1 2015 50
Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2015 51
Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H1 2015 52
Bladder Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2015 53
Bladder Cancer - Pipeline by Astellas Pharma Inc., H1 2015 54
Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2015 55
Bladder Cancer - Pipeline by AuraSense Therapeutics, LLC, H1 2015 56
Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 57
Bladder Cancer - Pipeline by AvidBiotics Corp., H1 2015 58
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2015 59
Bladder Cancer - Pipeline by Bayer AG, H1 2015 60
Bladder Cancer - Pipeline by BioCancell Ltd, H1 2015 61
Bladder Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2015 62
Bladder Cancer - Pipeline by Biotest AG, H1 2015 63
Bladder Cancer - Pipeline by cCAM Biotherapeutics Ltd., H1 2015 64
Bladder Cancer - Pipeline by Celgene Corporation, H1 2015 65
Bladder Cancer - Pipeline by Cold Genesys, Inc., H1 2015 66
Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 67
Bladder Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 68
Bladder Cancer - Pipeline by DormaTarg, Inc., H1 2015 69
Bladder Cancer - Pipeline by Eisai Co., Ltd., H1 2015 70
Bladder Cancer - Pipeline by Eli Lilly and Company, H1 2015 71
Bladder Cancer - Pipeline by EntreChem, S.L., H1 2015 72
Bladder Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 73
Bladder Cancer - Pipeline by Evotec AG, H1 2015 74
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 75
Bladder Cancer - Pipeline by Gene Signal International SA, H1 2015 76
Bladder Cancer - Pipeline by Genmab A/S, H1 2015 77
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015 78
Bladder Cancer - Pipeline by Heat Biologics, Inc., H1 2015 79
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 80
Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 81
Bladder Cancer - Pipeline by Immunomedics, Inc., H1 2015 82
Bladder Cancer - Pipeline by Immupharma Plc, H1 2015 83
Bladder Cancer - Pipeline by ImmuRx, Inc., H1 2015 84
Bladder Cancer - Pipeline by Incyte Corporation, H1 2015 85
Bladder Cancer - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 86
Bladder Cancer - Pipeline by MacroGenics, Inc., H1 2015 87
Bladder Cancer - Pipeline by Marina Biotech, Inc., H1 2015 88
Bladder Cancer - Pipeline by MedImmune, LLC, H1 2015 89
Bladder Cancer - Pipeline by Merck & Co., Inc., H1 2015 90
Bladder Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 91
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H1 2015 92
Bladder Cancer - Pipeline by NuCana BioMed Limited, H1 2015 93
Bladder Cancer - Pipeline by Omeros Corporation, H1 2015 94
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 95
Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 96
Bladder Cancer - Pipeline by Oncopeptides AB, H1 2015 97
Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 98
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H1 2015 99
Bladder Cancer - Pipeline by Panacela Labs, Inc., H1 2015 100
Bladder Cancer - Pipeline by Pfizer Inc., H1 2015 101
Bladder Cancer - Pipeline by Pharma Mar, S.A., H1 2015 102
Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 103
Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2015 104
Bladder Cancer - Pipeline by Qu Biologics Inc., H1 2015 105
Bladder Cancer - Pipeline by Quest PharmaTech Inc., H1 2015 106
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H1 2015 107
Bladder Cancer - Pipeline by Sanofi, H1 2015 108
Bladder Cancer - Pipeline by SentoClone International AB, H1 2015 109
Bladder Cancer - Pipeline by Serometrix, LLC, H1 2015 110
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H1 2015 111
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 112
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2015 113
Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 114
Bladder Cancer - Pipeline by TARIS BioMedical, Inc., H1 2015 115
Bladder Cancer - Pipeline by Telesta Therapeutics Inc., H1 2015 116
Bladder Cancer - Pipeline by Telormedix SA, H1 2015 117
Bladder Cancer - Pipeline by Theravectys S.A., H1 2015 118
Bladder Cancer - Pipeline by TheRyte Limited, H1 2015 119
Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 120
Bladder Cancer - Pipeline by Transgene SA, H1 2015 121
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H1 2015 122
Bladder Cancer - Pipeline by Viralytics Ltd., H1 2015 123
Bladder Cancer - Pipeline by Viventia Biotechnologies Inc., H1 2015 124
Assessment by Monotherapy Products, H1 2015 125
Assessment by Combination Products, H1 2015 126
Number of Products by Stage and Target, H1 2015 128
Number of Products by Stage and Mechanism of Action, H1 2015 133
Number of Products by Stage and Route of Administration, H1 2015 137
Number of Products by Stage and Molecule Type, H1 2015 139
Bladder Cancer Therapeutics - Recent Pipeline Updates, H1 2015 341
Bladder Cancer - Dormant Projects, H1 2015 448
Bladder Cancer - Dormant Projects (Contd..1), H1 2015 449
Bladder Cancer - Dormant Projects (Contd..2), H1 2015 450
Bladder Cancer - Dormant Projects (Contd..3), H1 2015 451
Bladder Cancer - Dormant Projects (Contd..4), H1 2015 452
Bladder Cancer - Dormant Projects (Contd..5), H1 2015 453
Bladder Cancer - Discontinued Products, H1 2015 454

List of Figures
Number of Products under Development for Bladder Cancer, H1 2015 22
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2015 23
Number of Products under Development by Companies, H1 2015 24
Number of Products under Investigation by Universities/Institutes, H1 2015 32
Comparative Analysis by Clinical Stage Development, H1 2015 34
Comparative Analysis by Early Stage Products, H1 2015 35
Assessment by Monotherapy Products, H1 2015 125
Assessment by Combination Products, H1 2015 126
Number of Products by Top 10 Targets, H1 2015 127
Number of Products by Stage and Top 10 Targets, H1 2015 127
Number of Products by Top 10 Mechanism of Actions, H1 2015 132
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 132
Number of Products by Top 10 Routes of Administration, H1 2015 136
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 136
Number of Products by Top 10 Molecule Types, H1 2015 138
Number of Products by Stage and Top 10 Molecule Types, H1 2015 138

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *